Targeted anti-ALK therapy has been shown to elicit good responses and dramatically prolong overall survival (OS) in patients with non-small cell lung cancer (NSCLC) harboring ALK rearrangement. This evidence concerns the gene ALK and non-small cell lung carcinoma.